A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS –FLI1 fusion transcript
ConclusionsHepatotoxicity precluded the administration of a mithramycin at a dose required to inhibit EWS –FLI1. Evaluation of mithramycin in patients selected for decreased susceptibility to elevated transaminases may allow for improved drug exposure.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Bone Cancers | Cancer | Cancer & Oncology | Chemotherapy | Children | Dexamethasone | Drugs & Pharmacology | Ewing's Sarcoma | Pediatrics | Sarcomas | Study | Toxicology